Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor-...

Area of Science:

• Oncology
• Cancer Research
• Angiogenesis Inhibition

Background:

• Targeting vascular endothelial growth factor (VEGF) combined with chemotherapy is effective for advanced cancers.
• Bevacizumab (BEV), an anti-VEGF monoclonal antibody, has renewed interest in antiangiogenic therapies as a complementary treatment modality.
• Novel antiangiogenic compounds are being developed, but their efficacy compared to BEV is still under investigation in clinical trials.

Purpose of the Study:

• To discuss the opportunities and obstacles in developing growth factor- and growth factor receptor-targeted antiangiogenic therapies for advanced cancers.
• To highlight the role of anti-VEGF therapies, including bevacizumab, in cancer treatment.
• To review ongoing clinical trials and the challenges in identifying surrogate markers for antiangiogenic drug efficacy.

Main Methods:

• Review of current literature on antiangiogenic therapies.
• Analysis of clinical trial data for anti-VEGF agents and novel inhibitors.
• Discussion of challenges in monitoring antiangiogenic drug activity.

Main Results:

• Combinatorial anti-VEGF therapy, exemplified by bevacizumab, has demonstrated success in advanced cancers.
• Second-generation multi-targeted tyrosine kinase inhibitors show potential but have not yet surpassed BEV efficacy in trials.
• Developing surrogate markers to monitor antiangiogenic drug efficacy is a critical challenge.

Conclusions:

• Antiangiogenic approaches, particularly targeting VEGF, are valuable in advanced cancer treatment.
• Further development involves adjuvant settings, combination therapies, and overcoming challenges in efficacy monitoring.
• Targeted antiangiogenic agents hold promise for various cancers, including malignant melanoma, with ongoing clinical evaluation.